Co-delivery with nano-quercetin enhances doxorubicin-mediated cytotoxicity against MCF-7 cells

Molecular Biology Reports

Volumn 43, Issue 2, 2016, Pages 99-105

  Minaei, Akbar ^a   Sabzichi, Mehdi ^b   Ramezani, Fatemeh ^c   Hamishehkar, Hamed ^d   Samadi, Nasser ^a,d  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chemoresistance; MCF 7; Phytosome; Quercetin

Indexed keywords

DOXORUBICIN; MESSENGER RNA; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; NANOPARTICLE; QUERCETIN; ANTINEOPLASTIC ANTIBIOTIC; DRUG CARRIER; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; NQO1 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG RELEASE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IC50; MCF 7 CELL LINE; MRP1 GENE; NANOENCAPSULATION; NQO1 GENE; PARTICLE SIZE; SCANNING ELECTRON MICROSCOPY; ZETA POTENTIAL; ANTAGONISTS AND INHIBITORS; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MCF-7 CELL LINE; METABOLISM; SIGNAL TRANSDUCTION; ULTRASTRUCTURE;

ANTIBIOTICS, ANTINEOPLASTIC; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; DOXORUBICIN; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NAD(P)H DEHYDROGENASE (QUINONE); NANOPARTICLES; PARTICLE SIZE; QUERCETIN; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84958182239     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-016-3942-x     Document Type: Article

References (46)

1. DeSantis C, Ma J, Bryan L, Jemal A (2014) Breast cancer statistics, 2013. CA Cancer J Clin 64(1):52–62
2. Gatti L, Zunino F (2005) Overview of tumor cell chemoresistance mechanisms. In: Blumenthal RD (ed) Chemosensitivity: Volume II. Springer, New York, pp 127–148
3. Li W-J, Zhong S-L, Wu Y-J, Xu W-D, Xu J-J, Tang J-H, Zhao J-H (2013) Systematic expression analysis of genes related to multidrug-resistance in isogenic docetaxel-and adriamycin-resistant breast cancer cell lines. Mol Biol Rep 40(11):6143–6150
4. Chang A (2011) Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 71(1):3–10
5. Fodale V, Pierobon M, Liotta L, Petricoin E (2011) Mechanism of cell adaptation: When and how do cancer cells develop chemoresistance? Cancer J 17(2):89–95
6. Cengiz E, Karaca B, Kucukzeybek Y, Gorumlu G, Gul MK, Erten C, Atmaca H, Uzunoglu S, Karabulut B, Sanli UA (2010) Overcoming drug resistance in hormone-and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination. Mol Biol Rep 37(3):1269–1277
7. Rejinold NS, Baby T, Nair SV, Jayakumar R (2013) Paclitaxel loaded fibrinogen coated CdTe/ZnTe core shell nanoparticles for targeted imaging and drug delivery to breast cancer cells. J Biomed Nanotechnol 9(10):1657–1671
8. Brannon-Peppas L, Blanchette JO (2012) Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 64:206–212
9. Vriend J, Reiter RJ (2015) The Keap1-Nrf2-antioxidant response element pathway: a review of its regulation by melatonin and the proteasome. Mol Cell Endocrinol 401:213–220
10. Wen X, Thorne G, Hu L, Joy, Aleksunes LM (2015) Activation of NRF2 signaling in HEK293 cells by a first‐in‐class direct KEAP1‐NRF2 inhibitor. J Biochem Mol Toxicol 29(6):261–266
11. Homma S, Ishii Y, Morishima Y, Yamadori T, Matsuno Y, Haraguchi N, Kikuchi N, Satoh H, Sakamoto T, Hizawa N (2009) Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 15(10):3423–3432
12. Lister A, Nedjadi T, Kitteringham NR, Campbell F, Costello E, Lloyd B, Copple IM, Williams S, Owen A, Neoptolemos JP (2011) Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Mol Cancer 10:37
13. Moon EJ, Giaccia A (2015) Dual roles of NRF2 in tumor prevention and progression: possible implications in cancer treatment. Free Radic Biol Med 79:292–299
14. Hou X, Bai X, Gou X, Zeng H, Xia C, Zhuang W, Chen X, Zhao Z, Huang M, Jin J (2015) 3′, 4′, 5′, 5, 7-Pentamethoxyflavone sensitizes cisplatin-resistant A549 cells to cisplatin by inhibition of Nrf2 pathway. Mol Cells 38(5):396–401
15. Valenzuela M, Glorieux C, Stockis J, Sid B, Sandoval J, Felipe K, Kviecinski M, Verrax J, Calderon PB (2014) Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells. Br J Cancer 111(5):874–882
16. Chian S, Thapa R, Chi Z, Wang XJ, Tang X (2014) Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo. Biochem Biophys Res Commun 447(4):602–608
17. Olayanju A, Copple IM, Bryan HK, Edge GT, Sison RL, Wong MW, Lai Z-Q, Lin Z-X, Dunn K, Sanderson CM (2015) Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity—implications for therapeutic targeting of Nrf2. Free Radic Biol Med 78:202–212
18. Sabzichi M, Hamishehkar H, Ramezani F, Sharifi S, Tabasinezhad M, Pirouzpanah M, Ghanbari P, Samadi N (2013) Luteolin-loaded phytosomes sensitize human breast carcinoma MDA-MB 231 cells to doxorubicin by suppressing Nrf2 mediated signalling. Asian Pac J Cancer Prev: APJCP 15(13):5311–5316
19. Kahraman A, Çakar H, Köken T (2012) The protective effect of quercetin on long-term alcohol consumption-induced oxidative stress. Mol Biol Rep 39(3):2789–2794
20. Sun M, Nie S, Pan X, Zhang R, Fan Z, Wang S (2014) Quercetin-nanostructured lipid carriers: characteristics and anti-breast cancer activities in vitro. Colloids Surf B 113:15–24
21. Amin T, Bhat SV (2012) A review on phytosome technology as a novel approach to improve the bioavailability of nutraceuticals. Int J Adv Res Technol 1(3):43–57
22. Patil M, Patil S, Chittam K, Wagh R (2012) Phytosomes: novel approach in herbal medicines. Asian J Pharm Sci Res 2:1–9
23. Jain N, Gupta BP, Thakur N, Jain R, Banweer J, Jain DK, Jain S (2010) Phytosome: a novel drug delivery system for herbal medicine. Int J Pharm Sci Drug Res 2(4):224–228
24. Chang C, Zhu Y, Tang X, Tao W (2011) The anti-proliferative effects of norcantharidin on human HepG2 cells in cell culture. Mol Biol Rep 38(1):163–169
25. Innamorato NG, Rojo AI, García-Yagüe ÁJ, Yamamoto M, De Ceballos ML, Cuadrado A (2008) The transcription factor Nrf2 is a therapeutic target against brain inflammation. J Immunol 181(1):680–689
26. Lee J-S, Surh Y-J (2005) Nrf2 as a novel molecular target for chemoprevention. Cancer Lett 224(2):171–184
27. Zhang P, Singh A, Yegnasubramanian S, Esopi D, Kombairaju P, Bodas M, Wu H, Bova SG, Biswal S (2010) Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther 9(2):336–346
28. Kweon M-H, Adhami VM, Lee J-S, Mukhtar H (2006) Constitutive overexpression of Nrf2-dependent heme oxygenase-1 in A549 cells contributes to resistance to apoptosis induced by epigallocatechin 3-gallate. J Biol Chem 281(44):33761–33772
29. Huang C-S, Lii C-K, Lin A-H, Yeh Y-W, Yao H-T, Li C-C, Wang T-S, Chen H-W (2013) Protection by chrysin, apigenin, and luteolin against oxidative stress is mediated by the Nrf2-dependent up-regulation of heme oxygenase 1 and glutamate cysteine ligase in rat primary hepatocytes. Arch Toxicol 87(1):167–178
30. Xu K, Liu B, Ma Y, Du J, Li G, Gao H, Zhang Y, Ning Z (2009) Physicochemical properties and antioxidant activities of luteolin-phospholipid complex. Molecules 14(9):3486–3493
31. Lopez-Lazaro M (2009) Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem 9(1):31–59
32. Akan Z, Garip AI (2013) Antioxidants may protect cancer cells from apoptosis signals and enhance cell viability. Asian Pac J Cancer Prev 14(8):4611–4614
33. Kawasaki Y, Ishigami S, Arigami T, Uenosono Y, Yanagita S, Uchikado Y, Kita Y, Nishizono Y, Okumura H, Nakajo A (2015) Clinicopathological significance of nuclear factor (erythroid-2)-related factor 2 (Nrf2) expression in gastric cancer. BMC Cancer 15(1):5
34. Liang G-Y, Lu S-X, Xu G, Liu X-D, Li J, Zhang D-S (2013) Expression of metallothionein and Nrf2 pathway genes in lung cancer and cancer-surrounding tissues. World J Surg Oncol 11(1):199
35. Akbas SH, Timur M, Ozben T (2005) The effect of quercetin on topotecan cytotoxicity in MCF-7 and MDA-MB 231 human breast cancer cells 1. J Surg Res 125(1):49–55
36. Paulhill KJ (2008) Quercetin and dietary lipids alter the cellular redox environment of the colonocyte in the promotion stage of colon carcinogenesis. Texas A&M University, College Station
37. Chen C, Zhou J, Ji C (2010) Quercetin: a potential drug to reverse multidrug resistance. Life Sci 87(11):333–338
38. Kim MK, K-s Park, Choo H, Chong Y (2015) Quercetin–POM (pivaloxymethyl) conjugates: modulatory activity for P-glycoprotein-based multidrug resistance. Phytomedicine 22(7):778–785
39. Bhattacharya S, Ghosh AK (2009) Phytosomes: the emerging technology for enhancement of bioavailability of botanicals and nutraceuticals. Int J Health Res 2(3):225–232
40. Suryawanshi S (2011) Phytosome: an emerging trend in herbal drug treatment. J Med Gene Geno 3:109–114
41. van Dijk C, Driessen AJ, Recourt K (2000) The uncoupling efficiency and affinity of flavonoids for vesicles. Biochem Pharmacol 60(11):1593–1600
42. Granado-Serrano AB, Martín M, Bravo L, Goya L, Ramos S (2012) Quercetin modulates Nrf2 and glutathione-related defenses in HepG2 cells: involvement of p38. Chem Biol Interact 195:154–164
43. Staedler D, Idrizi E, Kenzaoui BH, Juillerat-Jeanneret L (2011) Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells. Cancer Chemother Pharmacol 68(5):1161–1172
44. Ren D, Villeneuve NF, Jiang T, Wu T, Lau A, Toppin HA, Zhang DD (2011) Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci 108(4):1433–1438
45. Hayes JD, McMahon M (2009) NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 34(4):176–188
46. Laurand A, Laroche-Clary A, Larrue A, Huet S, Soma É, Bonnet J, Robert J (2004) Quantification of the expression of multidrug resistance-related genes in human tumour cell lines grown with free doxorubicin or doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres. Anticancer Res 24(6):3781–3788